WC
REGN icon

Waterloo Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Waterloo Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Sell
339
-62
-15% -$42.2K 0.01% 539
2026
Q1 		$310K Sell
401
-344
-46% -$263K 0.02% 388
2025
Q4 		$575K Buy
+745
New +$506K 0.04% 275

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Waterloo Capital's REGN Position: Q2 2026 in Review

Waterloo Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 15% in Q2 2026, selling an estimated $42.2K and leaving 339 shares worth $212K. The position accounts for 0.01% of the portfolio, ranked #539.

Waterloo Capital first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $575K in Q4 2025. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Waterloo Capital held 339 shares of Regeneron Pharmaceuticals worth $212K as of Q2 2026.
  • Waterloo Capital sold 62 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $42.2K.
  • Regeneron Pharmaceuticals made up 0.01% of Waterloo Capital's portfolio in Q2 2026, its #539 holding.
  • Waterloo Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Waterloo Capital's Regeneron Pharmaceuticals position peaked at $575K in Q4 2025.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Waterloo Capital's 13F filing for Q2 2026, filed 29 Jul 2026.